Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE aga... Mehr ...

Volltext
Verfasser: Woestenberg, Petra J.
King, Audrey J.
Van Benthem, Birgit H.B.
Leussink, Suzan
Van Der Sande, Marianne A.B.
Hoebe, Christian J.P.A.
Bogaards, Johannes A.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Reihe/Periodikum: Woestenberg , P J , King , A J , Van Benthem , B H B , Leussink , S , Van Der Sande , M A B , Hoebe , C J P A & Bogaards , J A 2020 , ' Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands ' , Journal of Infectious Diseases , vol. 221 , no. 8 , pp. 1280-1285 . https://doi.org/10.1093/infdis/jiz187
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29216222
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://research.vumc.nl/en/publications/8cdbee21-69c4-44bb-a620-b37edc6d7d26

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.